Overview

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to contribute, along with other such dose-finding studies, to the identification of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate cancer by a rapid and sustained suppression of testosterone.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals